43
Participants
Start Date
November 30, 2025
Primary Completion Date
January 1, 2027
Study Completion Date
January 1, 2028
BC3402
BC3402, intravenous, 20 mg/kg, D1 and D15 of every 28 day cycle, continuous. BC3402 to be administered after completion of the infusion of durvalumab and/or tremelimumab on the days when BC3402 is to be administered with durvalumab and/or tremelimumab
Durvalumab
Durvalumab, intravenous, 1500 mg, every 4 weeks, continuous
Tremelimumab
Tremelimumab, intravenous, 300 mg, 1 dose on Cycle 1 Day 1
Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center, Cleveland
Case Comprehensive Cancer Center
OTHER